US Bancorp DE has a $301,000 stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

US Bancorp DE increased its holdings in Fresenius Medical Care AG & Co. (SEC). The company owned 21,446 shares of the company after purchasing an additional 5,679 shares during the quarter. US Bancorp DE’s interests in Fresenius Medical Care AG & Co. KGaA were worth $301,000 at the end of the most recent quarter.

→ Is this the end of capitalism? (From Porter & Company)

Other hedge funds have also recently modified their holdings in the company. Wetherby Asset Management Inc. increased its position in Fresenius Medical Care AG & Co. KGaA at 9.0% in Q1. Wetherby Asset Management Inc. now owns 6,807 shares of the company valued at $229,000 after purchasing an additional 560 shares last quarter. Commonwealth Equity Services LLC has increased its stake in Fresenius Medical Care AG & Co. KGaA at 5.5% in Q2. Commonwealth Equity Services LLC now owns 14,070 shares of the company valued at $350,000 after purchasing an additional 736 shares during the period. CWM LLC has increased its shareholding in Fresenius Medical Care AG & Co. KGaA at 82.0% in the third quarter. CWM LLC now owns 1,753 shares of the company valued at $25,000 after purchasing an additional 790 shares during the period. National Bank of Canada FI increased its holdings in Fresenius Medical Care AG & Co. KGaA at 6.0% in the third quarter. National Bank of Canada FI now owns 17,737 shares of the company valued at $244,000 after purchasing an additional 1,006 shares in the last quarter. Finally, Scotia Capital Inc. increased its position in Fresenius Medical Care AG & Co. KGaA at 1.4% during the second quarter. Scotia Capital Inc. now owns 76,510 shares of the company worth $1,908,000 after purchasing an additional 1,065 shares during the period. Institutional investors and hedge funds own 5.56% of the company’s shares.

Analysts set new price targets

Several brokerages have recently issued reports on the FMS. Barclays lowered its price target on Fresenius Medical Care AG & Co. KGaA from €40.00 ($43.48) to €36.00 ($39.13) and established an “equal weight” rating for the stock in a research report on Friday, Oct. 28. StockNews.com cut Fresenius Medical Care AG & Co. KGaA from a “Strong Buy” rating to a “Buy” rating in a report on Wednesday, Dec. 28. JPMorgan Chase & Co. lowered its stock price target for Fresenius Medical Care AG & Co. KGaA from €23.00 ($25.00) to €17.10 ($18.59) in a research report on Tuesday, November 1st. Berenberg Bank has cut its stock price target for Fresenius Medical Care AG & Co. KGaA from €57.95 ($62.99) to €51.80 ($56.30) in a research report on Wednesday, Oct. Finally, Morgan Stanley lowered its price target on Fresenius Medical Care AG & Co. Three research analysts gave the stock a Sell rating, five assigned a Maintenance rating, and two issued a Buy rating for the company. Based on MarketBeat data, the company currently has an average rating of “hold” and an average price target of $35.96.

Stock Performance of Fresenius Medical Care AG & Co. KGaA

FMS opened at $18.04 on Wednesday. The company has a cash ratio of 0.96, a current ratio of 1.34 and a debt to equity ratio of 0.48. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $12.78 and a 12-month high of $35.04. The company has a 50-day moving average of $16.33 and a 200-day moving average of $16.68. The stock has a market cap of US$10.57 billion, a price/earnings ratio of 12.79 and a beta of 1.00.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last announced its quarterly results on Sunday, October 30th. The company reported earnings per share of $0.40 (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.03. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.03% and a net margin of 4.01%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $4.60 billion. On average, equity research analysts expect Fresenius Medical Care AG & Co. KGaA posts earnings of 1.43 per share for the current year.

Company Profile Fresenius Medical Care AG & Co. KGaA

(Get Review)

Fresenius Medical Care AG & Co KgaA provides products and services for individuals with kidney disease. The company develops and manufactures healthcare products, including dialysis and non-dialysis products. It operates in the following segments: North America Segment, EMEA Segment, Asia Pacific Segment and Latin America Segment.

See too

Institutional ownership by quarter for Fresenius Medical Care AG & Co.  KGaA (NYSE:FMS)

This instant news alert was powered by MarketBeat’s financial data and narrative science technology to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before considering Fresenius Medical Care AG & Co. KGaA, you’re going to want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients daily. MarketBeat has identified the five stocks that top analysts are whispering quietly to their customers to buy now before the broader market closes in… and Fresenius Medical Care AG & Co. KGaA was not on the list.

Although Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are the best buys.

See the five actions here

Elon Musk’s Next Step

Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click on the link below to find out when Elon Musk will allow these companies to finally IPO.

Get this free report

Cover of Elon Musk's Next Move
US Bancorp DE has a $301,000 stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Leave a Reply

Your email address will not be published.

Scroll to top